The first sham-controlled trial of atrial fibrillation ablation with pulmonary vein isolation shows a placebo-resistant benefit, but questions remain about how it works, writes John Mandrola, MD.
It's finally here. Twenty years and millions of procedures later, Rajdip Dulai, MBBS, and colleagues in the United Kingdom have presented positive results ofMany of my colleagues have long denied the need for a placebo-controlled trial. They argue that trials of ablation vs drugs show that ablation is superior in reducing AF episodes.
The authors measured QOL with three different scores. All three improved significantly more in the ablation arm. I had AF that resolved without a procedure over a year. At that time, my main worry was not AF but a deadly complication of ablation, such as atrial-esophageal fistula. Though these are rare events, the memory of seeing even one young person die from ablation sticks in your brain. After SHAM-PVI, an EP colleague wrote this to me via email:
AF Afib A-Fib Afib Afib Atrial Fib Atrial Fibrillation (AF) Atrial Fibrillation (A-Fib) AF - Atrial Fibrillation Ablation Stroke Risk Quality Of Life QOL Health Related Quality Of Life Health-Related Quality Of Life HRQOL Fellowship Fellows Residency Residents Veins Biventricular Pacing BIV Cardiac Resynchronization Therapy CRT
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Video: How the world’s first fully traceable tin mine works No 1 source of global mining news and opinion
Read more »
Mobile city council approves first female Public Works DirectorThe Mobile City Council unanimously approved Shonnda Smith as the Executive Director of Public Works on Tuesday. Smith has been serving in dual capacity as the
Read more »
Rams QB Matthew Stafford progresses in return to practiceRookie center Beaux Limmer impresses, works out with first team.
Read more »
'There’s nothing like it in town': America's first carbon-positive hotel coming to DenverLisa provides the latest First Alert Weather forecast on Denver7 starting at 4:30am every weekday morning.
Read more »
Ivonescimab: Possible New First-Line Standard in PD-L1-Positive Advanced NSCLC?The investigational PD-1/VEGF bi-specific immunotherapy agent showed a clinically significant progression-free survival over pembrolizumab in advanced PD-L1-positive NSCLC.
Read more »
'Euphoria' Season 3 Gets Its First Positive Update in a Long TimeDenis is a professional writer covering entertainment topics focusing on TV shows. He writes reviews and news for all genres.
Read more »